Development of new treatment strategies targeting IMP3 in uterine carcinosarcoma

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K20161
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: 独立行政法人国立病院機構(東京医療センター臨床研究センター) (2016-2017); Keio University (2015)
• Principal Investigator: Ueki Arisa 独立行政法人国立病院機構(東京医療センター臨床研究センター), その他部局等, 研究員 (60445319)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 子宮 / 癌肉腫 / IMP3 / エピジェネティクス

Outline of Final Research Achievements

IMP3 (Igf2 mRNA- binding protein 3) is regarded as a novel oncofetal protein expressed especially during early stage of embryogenesis, but also re-expressed in many malignant tissues. Here we found significant correlation between IMP3 expression and overall survival in human uterine carcinosarcoma (CS).
Histone modification status was also correlated to the IMP3 expression, and considered as an independent prognostic factor in CS. These findings suggested that IMP3 expression might confer epigenetic histone modification. To clarify further mechanical regulation on IMP3 leads to the establishment of new prognostic factors as well as solid therapeutic procedures in CS.

Free Research Field

婦人科腫瘍